Novo Nordisk (NYSE:NVO) received seven somewhat bullish analyst ratings in the last quarter, with a notable increase in the 12-month price target to $142.86 from $130.00, indicating a 9.89% rise. Analysts from firms like Cantor Fitzgerald and Morgan Stanley have maintained or raised their overweight ratings, reflecting positive expectations for the company's performance. Novo Nordisk, a leader in diabetes care, has shown strong financial health with a revenue growth of 36.95%, a net margin of 33.35%, and an ROE of 22.01%, outperforming industry averages.